| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
TORONTO—FACIT, a commercialization venture group, and the University of Toronto (U of T) have announced the creation of Ontario-based Cellular Analytics. Cellular Analytics is founded upon a proprietary microfluidic platform that enables molecular characterization of cancer at the level of single circulating tumour cells. The technology quantitatively detects sensitivity to immune-oncology agents “on-chip” at both significantly lower sample volumes and at a fraction of the cost.
 
The platform, with an initial application in lung cancer, was discovered at the U of T lab of Dr. Shana Kelley. The professor and serial entrepreneur will act as the chief scientific officer of Cellular Analytics.
 
“Dr. Kelley’s technology is rapid, exquisitely accurate and inexpensive, which positions the Company well for clinical application across a range of cancers and competing in the diagnostics market,” said Dr. David O’Neill, president, FACIT. “Partnering with the University of Toronto on exciting new biotechnology companies like Cellular Analytics is aligned with FACIT and OICR’s joint strategy to support entrepreneurship and translate the benefits of research to patients and the Ontario economy.”
 
Seed capital from FACIT’s Compass Rose Oncology Fund — which invests in Ontario-based breakthrough innovations in oncology — will be used to develop the non-invasive, commercial prototype of Cellular Analytics’ lead product. This capital will also allows Cellular Analytics to maintain its momentum and continue strategic discussions with potential partners and investors to attract follow-on financing.
 
To strengthen and anchor companies to the province, FACIT provides transition executive management through its Executive-in-Residence (EIR) program. Dr. Brent Zanke, a FACIT EIR and experienced commercial diagnostics expert in oncology, helped lead the formation of Cellular Analytics, and will transition to the role of president and CEO.
 
“The essence of precision medicine demands more sensitive and flexible diagnosis to accompany every new experimental therapy. Our CytoFind platform delivers on these challenges with unprecedented fidelity,” remarked Zanke.
 
Cellular Analytics will be a resident at Johnson & Johnson Innovation – JLABS @ Toronto, with additional in-kind support from FACIT and the Creative Destruction Labs (CDL).
 
“Congratulations to FACIT and U of T on this exciting new venture. The creation of this new company is a perfect example of how Ontario First capital can help bring the ground-breaking work being done at our world-class postsecondary institutions to market — helping to strengthen the province’s economy and generate innovation outcomes from the province’s top-tier scientific discoveries,” added Ross Romano, Ontario’s Minister of Colleges and Universities.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue